If mRNA drugs are likened to confidential life instructions sent to the inside of cells, lipid nanoparticles (LNPs) act as an elite escort team safeguarding these messages through numerous biological barriers. Without LNPs, these molecular messages cannot even begin their journey. This is not a matter of competing technical routes, but an inevitable outcome dictated by the inherent physicochemical properties of mRNA and the defense mechanisms of the human body. Grasping why mRNA relies heavily on LNPs lays the foundation for understanding the entire mRNA drug technology platform.
First Hurdle: The Chemical Fragility of mRNA
mRNA exists as a single-stranded nucleic acid and is chemically extremely unstable. Exposed mRNA is like a piece of paper caught in a violent storm when confronted with ribonucleases (RNases), which are ubiquitous throughout the human body. These enzymes can completely degrade unprotected mRNA within minutes. RNases are present in blood, tissue fluid, on cell surfaces and even in the air, serving as an evolutionary defense mechanism that eliminates foreign RNA.
Beyond enzymatic degradation, the chemical structure of mRNA itself is unstable. The 2′-hydroxyl group on its ribose ring makes the phosphodiester bonds prone to hydrolytic cleavage. Even in an enzyme-free environment, bare mRNA will degrade spontaneously within hours at room temperature. This intrinsic chemical instability means mRNA cannot be administered orally or via simple injection like small-molecule drugs.
The primary core function of LNPs is to physically protect mRNA. The nanoparticles encapsulate mRNA within their aqueous core, forming a dense lipid barrier that shields the payload from RNases and other degradative factors. This protection persists from the moment of injection throughout systemic circulation until LNPs reach target cells.
Second Hurdle: The Blockade of Cell Membranes
Even if mRNA evades degradation, it faces another fatal challenge: inability to penetrate cells. The cell membrane is a sophisticated barrier composed of a phospholipid bilayer, which only permits the passage of specific small molecules. mRNA is not only large in size (consisting of thousands of nucleotides) but also carries a strong negative charge.
Since the cell membrane surface is also negatively charged, electrostatic repulsion prevents bare mRNA from approaching, let alone crossing the membrane. Unencapsulated mRNA is trapped outside cells permanently and can never perform its core function of directing protein synthesis.
LNPs resolve this issue thanks to their unique formulation. Their key component, ionizable lipids, remains electrically neutral at physiological pH, eliminating electrostatic repulsion with cell membranes. Meanwhile, LNPs with a particle size of approximately 80 to 100 nanometers can be actively internalized by cells via endocytosis. In short, LNPs package the otherwise undeliverable molecular message into a cargo that cells readily take up.
Third Hurdle: The Endosomal Trap
Once internalized by cells, LNPs do not directly enter the cytoplasm. Instead, they become confined within membrane-bound vesicles called endosomes. Endosomes gradually acidify and eventually fuse with lysosomes — the cellular “digestive organelles” packed with enzymes that break down mRNA. If mRNA fails to escape the endosome, it will be fully degraded, rendering all prior efforts futile.
This represents the most sophisticated design feature of LNPs. The pKa value of ionizable lipids is precisely engineered to range from 6.0 to 6.5. In the acidic environment of endosomes, these lipids become positively charged. The resulting charge alteration triggers interactions with the endosomal membrane and disrupts its integrity, releasing mRNA into the cytoplasm — the site where ribosomes carry out protein synthesis. Without this endosomal escape capability, LNPs would be nothing more than elaborate cages.
Fourth Hurdle: Surveillance by the Immune System
Even after mRNA successfully enters the cytoplasm, it must evade the body’s innate immune system. Human cells are equipped with pattern recognition receptors that identify foreign RNA, such as viral genetic material. Activation of these receptors triggers robust inflammatory responses and inhibits protein translation.
This was a major bottleneck in early mRNA research: in vitro transcribed mRNA induced severe immune reactions, causing inflammation and suppressing the expression of target proteins. A groundbreaking discovery by Katalin Karikó and Drew Weissman in 2005 reversed this situation. Replacing uridine with pseudouridine drastically reduced the immunogenicity of mRNA. In addition, PEGylated lipids in LNPs act as a “stealth coating” to evade immune recognition, and encapsulation further limits contact between mRNA and immune receptors.
An All-in-One Solution to Delivery Challenges
Each of the aforementioned obstacles can be addressed with standalone strategies: RNase inhibitors slow down degradation, electroporation facilitates cellular uptake, and chemical modifications lower immunogenicity. However, these individual approaches cannot be combined into a safe, effective delivery system suitable for clinical use in humans.
The unique strength of LNPs lies in their capacity to tackle all challenges with a single platform. They protect mRNA from degradation, mediate cellular uptake, enable endosomal escape, mitigate immune responses, and support large-scale manufacturing and clinical application. From chemical protection and physical transportation to cellular internalization and endosomal release, LNPs play an irreplaceable role at every stage of the delivery pathway.
Consequences of LNP Absence
Without LNPs, mRNA possesses virtually no therapeutic value in vivo. Naked mRNA administered intravenously is degraded by RNases within minutes. Even if a small fraction enters cells via local injection, it will be trapped and broken down in endosomes. The few molecules that manage to escape into the cytoplasm may trigger intense immune reactions and block protein translation.
Before the maturation of LNP technology, the development of mRNA therapeutics stagnated. Advances in LNPs transformed mRNA from a laboratory research tool into a clinically viable therapeutic platform. The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman for discovering that nucleoside modifications reduce mRNA immunogenicity. Nonetheless, LNPs were equally instrumental in translating this scientific breakthrough into vaccines that have saved countless lives worldwide.
Conclusion
The relationship between mRNA and LNPs goes far beyond that of a drug and a simple excipient — they form an inseparable partnership. Without LNPs, mRNA cannot survive in the body, enter cells, escape endosomes, or be translated by ribosomes. mRNA carries therapeutic genetic information, while LNPs create the pathway for this information to reach its destination.
Understanding why mRNA requires LNPs is the starting point for comprehending the underlying logic of mRNA drug technology. mRNA is not a conventional drug, but a set of biological instructions that require protection, delivery and controlled release. Likewise, LNPs are not merely inert diluents, but sophisticated vehicles that transport these vital instructions across a series of formidable biological barriers.
